An Open-label Multicenter Multicohort Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors

Brief description of study

The purpose of the study is to assess the antitumor activity and safety of enfortumab vedotin as a single agent in adult subjects who have locally advanced or metastatic malignant solid tumors and have progressed on prior standard anticancer treatment(s). We want to know if study investigational drug enfortumab vedotin is effective and safe as a treatment for people with breast cancer. Researchers will look at how enfortumab vedotin can act in the body. Enfortumab vedotin is an experimental study medicine that is being studied to treat breast cancer in this research trial. The Food and Drug Administration (FDA) has approved PADCEV™ (enfortumab vedotin) to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter, or urethra). However, enfortumab vedotin is not approved for use for any other indications, including the type of cancer being researched in this clinical trial, or in any other countries (i.e. Pharmaceuticals and Medical Devices Agency (PMDA) or Health Canada).

Clinical Study Identifier: s19-00719 Identifier: NCT04225117

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.